Enliven Therapeutics Inc (ELVN)

$46.41 -1.70 (-3.53%)
Market Cap 2.93B
Revenue (ttm) 0.00
Net Income (ttm) -103.69M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 492,300
Avg Vol 1,219,850
Day's Range N/A - N/A
Shares Out 60.90M
Stochastic %K 96%
Beta 0.26
Analysts Strong Sell
Price Target $49.12

Company Profile

Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its clinical programs comprise ELVN-001, a small molecule kinase inhibitor which is in Phase 1 clinical trial to treat adults with chronic myeloid leukemia; and ELVN-002, a central nervous system (CNS) penetrant and irreversible human epidermal growth factor receptor 2 inhibitor that is in Phase 1 clinical trial for the treatm...

Industry: Biotechnology
Sector: Healthcare
Phone: 720 647 8519
Address:
6200 Lookout Road, Boulder, United States
blue81
blue81 Apr. 18 at 10:58 AM
$ELVN mm know dmr will be 40 percent and up. , next month we will. See where data will Fall 🍁🍁🍁🍁
0 · Reply
Whiskeyunderthebed
Whiskeyunderthebed Apr. 17 at 8:04 PM
$ELVN crazy stuff!
0 · Reply
thedentite
thedentite Apr. 17 at 5:13 PM
$ELVN This is getting kind of crazy. I tried to tell my $ALT buddies a while ago but they weren’t interested. I will say that board has way better posts though…
0 · Reply
AC_TRADER
AC_TRADER Apr. 16 at 5:42 AM
$ELVN +40% as seen below ✅
0 · Reply
thedentite
thedentite Apr. 14 at 3:23 PM
$ELVN So strong
0 · Reply
thedentite
thedentite Apr. 10 at 6:53 PM
$ELVN yeeeeeahhhhh! Nothing can stop the ELVN. I hope my $ALT friends come over and see. I first mentioned this at 15.1. People, this stock doesn’t stop going up. I moved a good chunk of alt over to it.
1 · Reply
Whiskeyunderthebed
Whiskeyunderthebed Apr. 10 at 2:41 PM
$ELVN this will turn green soon.
0 · Reply
blue81
blue81 Apr. 9 at 7:41 PM
$ELVN it's look like the market maker know that the dmr in the summer will be more than 40%
0 · Reply
thedentite
thedentite Apr. 9 at 6:14 PM
$ELVN Why aren't more people piling into this stock? It just keeps going up. Kicking myself for not pouring everything into it at 15.1 but who knew?
1 · Reply
thedentite
thedentite Apr. 9 at 2:08 PM
$ELVN I studied the chart, and technicals are looking great.
0 · Reply
Latest News on ELVN
Enliven Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference

Feb 25, 2026, 4:05 PM EST - 7 weeks ago

Enliven Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference

Enliven Therapeutics Early Leukemia Drug Results Impress, Stock Soars

Jan 8, 2026, 2:16 PM EST - 3 months ago

Enliven Therapeutics Early Leukemia Drug Results Impress, Stock Soars

Enliven Reports Positive Initial Phase 1b Data for ELVN-001 in CML and Outlines 2026 Clinical Milestones

Jan 8, 2026, 9:00 AM EST - 3 months ago

Enliven Reports Positive Initial Phase 1b Data for ELVN-001 in CML and Outlines 2026 Clinical Milestones

Enliven Therapeutics Bolsters Board to Prepare for Next Phase of Development

Jan 7, 2026, 9:00 AM EST - 3 months ago

Enliven Therapeutics Bolsters Board to Prepare for Next Phase of Development

Enliven Therapeutics Reports Inducement Grants as Permitted by the Nasdaq Listing Rules

Dec 11, 2025, 4:21 PM EST - 4 months ago

Enliven Therapeutics Reports Inducement Grants as Permitted by the Nasdaq Listing Rules

Enliven Therapeutics Announces New CEO to Drive Next Phase of Development

Dec 11, 2025, 9:00 AM EST - 4 months ago

Enliven Therapeutics Announces New CEO to Drive Next Phase of Development

Enliven Therapeutics Reports Third Quarter Financial Results and Provides a Business Update

Nov 12, 2025, 4:05 PM EST - 5 months ago

Enliven Therapeutics Reports Third Quarter Financial Results and Provides a Business Update

Enliven Therapeutics Announces Oral and Poster Presentations at the Society of Hematologic Oncology (SOHO) 2025 Annual Meeting

Aug 25, 2025, 6:20 PM EDT - 8 months ago

Enliven Therapeutics Announces Oral and Poster Presentations at the Society of Hematologic Oncology (SOHO) 2025 Annual Meeting

Enliven Therapeutics Reports Second Quarter Financial Results and Provides a Business Update

Aug 13, 2025, 4:05 PM EDT - 8 months ago

Enliven Therapeutics Reports Second Quarter Financial Results and Provides a Business Update

Enliven Therapeutics Announces Closing of Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional Shares

Jun 16, 2025, 4:05 PM EDT - 11 months ago

Enliven Therapeutics Announces Closing of Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional Shares

Enliven Therapeutics Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants

Jun 13, 2025, 9:30 AM EDT - 11 months ago

Enliven Therapeutics Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants

Enliven Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

Jun 13, 2025, 6:10 AM EDT - 11 months ago

Enliven Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

Enliven Therapeutics Announces Updated Positive Data from Phase 1 Clinical Trial of ELVN-001 in CML at EHA 2025 Congress

Jun 13, 2025, 6:02 AM EDT - 11 months ago

Enliven Therapeutics Announces Updated Positive Data from Phase 1 Clinical Trial of ELVN-001 in CML at EHA 2025 Congress

Enliven Therapeutics to Present at Upcoming Investor Conferences

May 22, 2025, 4:05 PM EDT - 11 months ago

Enliven Therapeutics to Present at Upcoming Investor Conferences

Enliven Therapeutics Reports First Quarter Financial Results and Provides a Business Update

May 14, 2025, 4:05 PM EDT - 1 year ago

Enliven Therapeutics Reports First Quarter Financial Results and Provides a Business Update

Enliven Therapeutics Announces Updated Positive Data from Phase 1 Clinical Trial of ELVN-001 in CML and Oral Presentation at the EHA 2025 Congress

May 14, 2025, 9:56 AM EDT - 1 year ago

Enliven Therapeutics Announces Updated Positive Data from Phase 1 Clinical Trial of ELVN-001 in CML and Oral Presentation at the EHA 2025 Congress

Enliven Therapeutics Announces Poster Presentations at the 2025 AACR Annual Meeting

Apr 2, 2025, 4:03 PM EDT - 1 year ago

Enliven Therapeutics Announces Poster Presentations at the 2025 AACR Annual Meeting

Final Trade: CVX, XLE, ELVN, COF

Mar 21, 2025, 6:38 PM EDT - 1 year ago

Final Trade: CVX, XLE, ELVN, COF

CVX XLE COF

Enliven Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update

Mar 13, 2025, 4:05 PM EDT - 1 year ago

Enliven Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update

Enliven Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference

Feb 25, 2025, 4:05 PM EST - 1 year ago

Enliven Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference

Biotech walks a 'tightrope' amid unclear funding, regulations

Jan 30, 2025, 7:06 PM EST - 1 year ago

Biotech walks a 'tightrope' amid unclear funding, regulations

DCTH IBB

Enliven Therapeutics to Present at the Jefferies London Healthcare Conference

Nov 7, 2024, 4:05 PM EST - 1 year ago

Enliven Therapeutics to Present at the Jefferies London Healthcare Conference

Why Enliven is this analyst's top biotech stock pick

Oct 18, 2024, 7:18 PM EDT - 1 year ago

Why Enliven is this analyst's top biotech stock pick

Enliven Therapeutics Announces Positive Data Update from Phase 1 Clinical Trial of ELVN-001 in Chronic Myeloid Leukemia

Sep 28, 2024, 9:35 AM EDT - 1 year ago

Enliven Therapeutics Announces Positive Data Update from Phase 1 Clinical Trial of ELVN-001 in Chronic Myeloid Leukemia

Enliven Therapeutics Announces Details Regarding the Presentation of Updated ELVN-001 Phase 1a Data at the ESH-iCMLf 26th Annual John Goldman Conference on CML

Sep 18, 2024, 4:05 PM EDT - 1 year ago

Enliven Therapeutics Announces Details Regarding the Presentation of Updated ELVN-001 Phase 1a Data at the ESH-iCMLf 26th Annual John Goldman Conference on CML

Enliven Therapeutics to Present at Two Upcoming Investor Conferences

May 29, 2024, 4:05 PM EDT - 2 years ago

Enliven Therapeutics to Present at Two Upcoming Investor Conferences

Enliven Therapeutics Announces Positive Proof of Concept Data from Phase 1 Clinical Trial of ELVN-001 in Chronic Myeloid Leukemia

Apr 11, 2024, 7:55 AM EDT - 2 years ago

Enliven Therapeutics Announces Positive Proof of Concept Data from Phase 1 Clinical Trial of ELVN-001 in Chronic Myeloid Leukemia

Enliven Therapeutics Appoints Dr. Lori Kunkel to Board of Directors

Apr 9, 2024, 4:05 PM EDT - 2 years ago

Enliven Therapeutics Appoints Dr. Lori Kunkel to Board of Directors

Enliven Therapeutics to Share Initial Proof of Concept Data from Phase 1 Clinical Trial of ELVN-001 and Host Virtual Key Opinion Leader Event on April 11, 2024

Mar 28, 2024, 4:05 PM EDT - 2 years ago

Enliven Therapeutics to Share Initial Proof of Concept Data from Phase 1 Clinical Trial of ELVN-001 and Host Virtual Key Opinion Leader Event on April 11, 2024

Enliven Therapeutics Announces $90 Million Private Placement Financing and Provides Pipeline Updates

Mar 19, 2024, 8:30 AM EDT - 2 years ago

Enliven Therapeutics Announces $90 Million Private Placement Financing and Provides Pipeline Updates

Enliven Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Business Update

Mar 14, 2024, 4:05 PM EDT - 2 years ago

Enliven Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Business Update

Enliven Therapeutics to Present at TD Cowen's 44th Annual Health Care Conference

Feb 27, 2024, 4:05 PM EST - 2 years ago

Enliven Therapeutics to Present at TD Cowen's 44th Annual Health Care Conference

Enliven Therapeutics Reports Second Quarter 2023 Financial Results and Highlights Recent Company Progress

Aug 10, 2023, 4:05 PM EDT - 2 years ago

Enliven Therapeutics Reports Second Quarter 2023 Financial Results and Highlights Recent Company Progress

Enliven Therapeutics Closes Merger with Imara and Private Placement of $165 Million

Feb 23, 2023, 5:20 PM EST - 3 years ago

Enliven Therapeutics Closes Merger with Imara and Private Placement of $165 Million

Imara Announces Stockholder Approval of Merger With Enliven

Feb 22, 2023, 4:01 PM EST - 3 years ago

Imara Announces Stockholder Approval of Merger With Enliven

IMARA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Imara Inc. - IMRA

Jan 25, 2023, 1:07 PM EST - 3 years ago

IMARA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Imara Inc. - IMRA

Enliven Therapeutics and Imara Announce Merger Agreement

Oct 13, 2022, 4:35 PM EDT - 3 years ago

Enliven Therapeutics and Imara Announce Merger Agreement

Read Why Imara Shares Are Falling Today

Apr 5, 2022, 10:13 AM EDT - 4 years ago

Read Why Imara Shares Are Falling Today

Imara Announces Results of Interim Analyses of Tovinontrine (IMR-687) Phase 2b Clinical Trials in Sickle Cell Disease and Beta-Thalassemia

Apr 5, 2022, 6:45 AM EDT - 4 years ago

Imara Announces Results of Interim Analyses of Tovinontrine (IMR-687) Phase 2b Clinical Trials in Sickle Cell Disease and Beta-Thalassemia

Imara to Webcast Conference Call of Full Year 2021 Financial Results and Business Highlights

Mar 8, 2022, 7:00 AM EST - 4 years ago

Imara to Webcast Conference Call of Full Year 2021 Financial Results and Business Highlights

Imara to Present at 11th Annual SVB Leerink Global Healthcare Conference

Feb 10, 2022, 7:00 AM EST - 4 years ago

Imara to Present at 11th Annual SVB Leerink Global Healthcare Conference

Imara To Start Testing Tovinontrine In Heart Failure Patients

Jan 25, 2022, 11:03 AM EST - 4 years ago

Imara To Start Testing Tovinontrine In Heart Failure Patients

Imara Announces FDA Clearance of Investigational New Drug Application (IND) for Tovinontrine (IMR-687) for Heart Failure with Preserved Ejection Fraction (HFpEF)

Jan 25, 2022, 7:00 AM EST - 4 years ago

Imara Announces FDA Clearance of Investigational New Drug Application (IND) for Tovinontrine (IMR-687) for Heart Failure with Preserved Ejection Fraction (HFpEF)

Imara to Present at the H.C. Wainwright BioConnect 2022 Virtual Conference

Jan 5, 2022, 7:00 AM EST - 4 years ago

Imara to Present at the H.C. Wainwright BioConnect 2022 Virtual Conference

Imara Presents Preclinical Data on IMR-261 at the American Society of Hematology (ASH) Annual Meeting 2021

Dec 14, 2021, 7:00 AM EST - 4 years ago

Imara Presents Preclinical Data on IMR-261 at the American Society of Hematology (ASH) Annual Meeting 2021

Imara Changes Primary Endpoint In Mid-Stage Sickle Cell Disease Trial

Nov 22, 2021, 10:36 AM EST - 4 years ago

Imara Changes Primary Endpoint In Mid-Stage Sickle Cell Disease Trial

Imara Announces Primary Endpoint Change in the Ardent Phase 2b Clinical Trial of Tovinontrine (IMR-687) in Sickle Cell Disease

Nov 22, 2021, 7:00 AM EST - 4 years ago

Imara Announces Primary Endpoint Change in the Ardent Phase 2b Clinical Trial of Tovinontrine (IMR-687) in Sickle Cell Disease

Imara's Thalassemia Candidate Shows Reduced Transfusion Burden At Higher Dose

Nov 16, 2021, 11:34 AM EST - 4 years ago

Imara's Thalassemia Candidate Shows Reduced Transfusion Burden At Higher Dose

blue81
blue81 Apr. 18 at 10:58 AM
$ELVN mm know dmr will be 40 percent and up. , next month we will. See where data will Fall 🍁🍁🍁🍁
0 · Reply
Whiskeyunderthebed
Whiskeyunderthebed Apr. 17 at 8:04 PM
$ELVN crazy stuff!
0 · Reply
thedentite
thedentite Apr. 17 at 5:13 PM
$ELVN This is getting kind of crazy. I tried to tell my $ALT buddies a while ago but they weren’t interested. I will say that board has way better posts though…
0 · Reply
AC_TRADER
AC_TRADER Apr. 16 at 5:42 AM
$ELVN +40% as seen below ✅
0 · Reply
thedentite
thedentite Apr. 14 at 3:23 PM
$ELVN So strong
0 · Reply
thedentite
thedentite Apr. 10 at 6:53 PM
$ELVN yeeeeeahhhhh! Nothing can stop the ELVN. I hope my $ALT friends come over and see. I first mentioned this at 15.1. People, this stock doesn’t stop going up. I moved a good chunk of alt over to it.
1 · Reply
Whiskeyunderthebed
Whiskeyunderthebed Apr. 10 at 2:41 PM
$ELVN this will turn green soon.
0 · Reply
blue81
blue81 Apr. 9 at 7:41 PM
$ELVN it's look like the market maker know that the dmr in the summer will be more than 40%
0 · Reply
thedentite
thedentite Apr. 9 at 6:14 PM
$ELVN Why aren't more people piling into this stock? It just keeps going up. Kicking myself for not pouring everything into it at 15.1 but who knew?
1 · Reply
thedentite
thedentite Apr. 9 at 2:08 PM
$ELVN I studied the chart, and technicals are looking great.
0 · Reply
Spicy_Trade
Spicy_Trade Apr. 9 at 12:12 AM
SpicyTrade Enliven Therapeutics, Inc. ( $ELVN ) daily stock analysis https://youtu.be/L1GyRnTRYVE?si=06UKIQTwsPeR5e7W
0 · Reply
thedentite
thedentite Apr. 8 at 2:19 PM
$ELVN Hey, stop doing that.
0 · Reply
RunnerSignals
RunnerSignals Apr. 7 at 8:17 PM
market warriors flipped the script $PSKY $HTZ $BKSY $ELVN $FRPT went red to green fast
0 · Reply
SerpentHalo
SerpentHalo Apr. 7 at 7:22 PM
$ELVN
0 · Reply
RunnerSignals
RunnerSignals Apr. 7 at 3:26 PM
$CAR $SSL $APLS $AA $ELVN highs are printing but volume not confirming across the board
0 · Reply
thedentite
thedentite Apr. 7 at 1:52 PM
$ELVN Somebody knows something.
1 · Reply
thedentite
thedentite Apr. 6 at 3:40 PM
$ELVN Nice, we are holding 40
0 · Reply
thedentite
thedentite Apr. 1 at 11:35 PM
$ELVN Rough end to the day there. We'll get them tomorrow.
0 · Reply
STACKD0E
STACKD0E Apr. 1 at 4:43 AM
$ELVN 🙃✨️So close
0 · Reply
Spicy_Trade
Spicy_Trade Mar. 28 at 6:56 PM
SpicyTrade Enliven Therapeutics, Inc. ( $ELVN ) daily stock analysis https://youtu.be/afDwMeMmMmQ?si=4x-PLja7Ym4GVUf0
0 · Reply
WycklyTrader
WycklyTrader Mar. 26 at 7:55 PM
Friday momo watch: $KOD $KALV $RLAY $ELVN $PGEN $ PLYX...
0 · Reply
naz2hi
naz2hi Mar. 26 at 5:45 PM
$ELVN $KOD ... might be safer to sit out this Trumpenstein zio-warmongering feuled mkt collapse w/ these winners. Now🙏 the 🍊 f*cktard doesn't actually go thru w/ his asinine plan of trying to invade Iran w/ marines. Which will probably lead in them getting killed and oil 🛢️ shooting up instantaneous to over $150, or possibly higher. As well as ushering in a worldwide economy disaster not seen in almost 100 yrs.
0 · Reply